Synthesis, X-Ray Crystal Structure, Hirshfeld Surface Analysis, and Molecular Docking Study of Novel Hepatitis B (HBV) Inhibitor: 8-Fluoro-5-(4-fluorobenzyl)-3-(2-methoxybenzyl)-3,5-dihydro-4H-pyrimido[5,4-b]indol-4-one
ABCD PBi
Synthesis, X-Ray Crystal Structure, Hirshfeld Surface Analysis, and Molecular Docking Study of Novel Hepatitis B (HBV) Inhibitor: 8-Fluoro-5-(4-fluorobenzyl)-3-(2-methoxybenzyl)-3,5-dihydro-4H-pyrimido[5,4-b]indol-4-one
Autor:
Ivashchenko, Aleksandr V.
;
Mitkin, Oleg D.
;
Kravchenko, Dmitry V.
;
Kuznetsova, Irina V.
;
Kovalenko, Sergiy M.
;
Bunyatyan, Natalya D.
;
Langer, Thierry
Assuntos:
1H-indole
;
3,5-dihydro-4H-pyrimido[5,4-b]indol-4-one
;
Acetonitrile
;
Biological activity
;
Chemical bonds
;
Crystal structure
;
Crystallization
;
Cytotoxicity
;
Drugs
;
HBV
;
Hepatitis B
;
Hirshfeld surface analysis
;
hydrogen bond
;
Hydrogen bonds
;
Infections
;
Inhibitors
;
Ligands
;
Molecular docking
;
molecular docking study
;
Molecular structure
;
pharmaceutical crystals
;
pyrimidin-4(3H)-one
;
Single crystals
;
Surface analysis (chemical)
;
Unit cell
;
Viral infections
;
X ray analysis
É parte de:
Crystals (Basel), 2019-08, Vol.9 (8), p.379
Descrição:
A method for the synthesis of 8-fluoro-5-(4-fluorobenzyl)-3-(2-methoxybenzyl)-3,5-dihydro-4H-pyrimido[5,4-b]indol-4-one has been developed and the electronic and spatial structure of a new biologically active molecule has been studied both theoretically and experimentally. The title compound was crystallized from acetonitrile and the single-crystal X-ray analysis has revealed that it exists in a monoclinic P21/n space group, with one molecule in the asymmetric part of the unit cell, a = 16.366(3) Å, b = 6.0295(14) Å, c = 21.358(4) Å, β = 105.21(2)°, V = 2033.7(7) Å3 and Z = 4. Hirshfeld surface analysis was used to study intermolecular interactions in the crystal. Molecular docking studies have evaluated the investigated compound as a new inhibitor of hepatitis B. Testing for anti-hepatitis B virus activity has shown that this substance has in vitro nanomolar inhibitory activity against Hepatitis B virus (HBV).
Editor:
Basel: MDPI AG
Idioma:
Inglês